Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

被引：0
|
作者：
Amrein, Philip C.
Attar, Eyal C.
Fathi, Amir Tahmasb
McAfee, Steven L.
Wadleigh, Martha
DeAngelo, Daniel J.
Steensma, David P.
Foster, Julia
Stone, Richard M.
Neuberg, Donna S.
Ballen, Karen K.
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[2] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6621
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [42] Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    OdchimarReissig, Rosalie
    Pemmaraju, Naveen
    Alvarado, Yesid
    Ohanian, Maro N.
    John, Rosmy B.
    Demakos, Erin P.
    Zbyszewski, Patrick S.
    Maniar, Manoj
    Woodman, Richard C.
    Fruchtman, Steven M.
    Silverman, Lewis R.
    LEUKEMIA RESEARCH, 2020, 94
  • [43] Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
    U Platzbecker
    F Braulke
    A Kündgen
    K Götze
    G Bug
    C Schönefeldt
    K Shirneshan
    C Röllig
    M Bornhäuser
    R Naumann
    J Neesen
    A Giagounidis
    W-K Hofmann
    G Ehninger
    U Germing
    D Haase
    M Wermke
    Leukemia, 2013, 27 : 1403 - 1407
  • [44] Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
    Platzbecker, U.
    Braulke, F.
    Kuendgen, A.
    Goetze, K.
    Bug, G.
    Schoenefeldt, C.
    Shirneshan, K.
    Roellig, C.
    Bornhaeuser, M.
    Naumann, R.
    Neesen, J.
    Giagounidis, A.
    Hofmann, W-K
    Ehninger, G.
    Germing, U.
    Haase, D.
    Wermke, M.
    LEUKEMIA, 2013, 27 (06) : 1403 - 1407
  • [45] EXTRAMEDULLARY LEUKEMIA (EML) IN MYELODYSPLASTIC SYNDROMES (MDS) - NOT A TRUE INDICATION OF IMPENDING ACUTE MYELOID-LEUKEMIA (AML)
    EDENFIELD, WJ
    BYRD, JC
    AYLESWORTH, C
    DOW, NS
    DAWSON, N
    BLOOD, 1994, 84 (10) : A631 - A631
  • [46] Preliminary results from a phase I study of Revlimid® (Lenalidomide) in combination with Vidaza® (Azacitidine) in patients with advanced myelodysplastic syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan
    Cuthbertson, David
    Paquette, Ronald
    Loughran, Thomas
    Maciejewski, Jaroslaw P.
    BLOOD, 2007, 110 (11) : 437A - 437A
  • [47] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [48] LOW-DOSE CYTARABINE (ARA-C) IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML)
    MUFTI, GJ
    OSCIER, DG
    HAMBLIN, TJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (03) : 571 - 571
  • [49] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [50] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    BLOOD, 2012, 120 (21)
12345